Exelixis: A Strong Contender in the Cancer Drug Market
Explore the exciting world of Exelixis (NASDAQ: EXEL) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
*Stock prices used were the prices of Feb. 11, 2026. The video was published on March 31, 2026.
Should you buy stock in Exelixis right now?
Before you buy stock in Exelixis, consider this:
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Exelixis wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $501,381!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,012,581!*
Now, it’s worth noting Stock Advisor’s total average return is 880% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of March 31, 2026.
Anand Chokkavelu has no position in any of the stocks mentioned. Karl Thiel has positions in Exelixis. Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Exelixis. The Motley Fool has a disclosure policy.
Recommended Articles
